ACC 23: Efficacy and Safety of MK-0616 In Hypercholesterolemia Patients

Подробнее о видео

We are joined by Dr Christie Ballantyne (Baylor College of Medicine, US) to discuss the results of a phase 2b clinical trial on the efficacy and safety of MK-0616, an oral macrocyclic PCSK9 inhibitor.

In this trial sponsored by Merck Sharp & Dohme LLC, MK-0616 was compared to a placebo in over 380 participants with hypercholesterolemia, whose low-density lipoprotein cholesterol (LDL-C) was measured over 8 weeks.

Results suggest that MK-0616 is safe and effective, with significant LDL cholesterol reduction.

Questions:
-What is the importance of this trial?
-Please outline the patient population and study design.
-What are the key findings?
-What are the clinical implications of these findings?
-What are the next steps for MK-0616?

For more content from ACC.23/WCC and the Late-breaker Discussion series head to Late-Breaking Science Video Collection.

Recorded on site at ACC 2023, New Orleans.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter: